CARsgen Presents Preliminary Results of CAR-BCMA T Cell Therapy at ASH 2018
Dec 04, 2018

SHANGHAI, Dec. 4, 2018 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage company committed to developing Chimeric Antigen Receptor T cell therapies for cancer, presented initial safety and efficacy results from its ongoing investigational study of CT053 for patients with relapsed/refractory multiple myeloma (R/R MM) at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego.